Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers

Fulvio Borella, MD 1, Stefano Cosma, MD, PhD 1, Domenico Ferraioli, MD, PhD 2, Isabelle Ray-Coquard, MD, PhD 2, Nicolas Chopin, MD 2, Pierre Meeus, MD 2, Vincent Cockenpot, MD 2, Giorgio Valabrega, MD, PhD 3, Giulia Scotto, MD 1, Margherita Turinetto, MD 3, Nicoletta Biglia, MD, PhD 4, Luca Fuso, MD, PhD 4, Luca Mariani, MD, PhD 4, Dorella Franchi, MD 5, Ailyn Mariela Vidal Urbinati, MD 5, Ida Pino, MD 5, Gianluca Bertschy, MD 1, Mario Preti, MD 1, Chiara Benedetto, MD, PhD 1, Isabella Castellano, MD, PhD 6, Paola Cassoni, MD, PhD 6, and Luca Bertero, MD, PhD 6

1Division of Gynecology and Obstetrics, Department of Surgical Sciences, University Hospital, University of Turin, Turin, Italy; 2Léon Bérard Comprehensive Cancer Center, Lyon, France; 3Department of Oncology, University of Turin, Turin, Italy; 4Division of Obstetrics and Gynecology - A.O. Ordine Mauriziano, University of Turin, Turin, Italy; 5Preventive Gynecology Unit, European Institute of Oncology IRCCS, Milan, Italy; 6Pathology Unit, Department of Medical Sciences, University and City of Health and Science, Turin, Italy

ABSTRACT

Background. The term uterine smooth muscle tumor of uncertain malignant potential (STUMP) indicates a rare, equivocal entity between benign leiomyomas and leiomyosarcomas. In the present study, we evaluated a comprehensive range of clinical, surgical, and pathological features in a large multicenter series of patients with STUMP to identify risk factors for recurrence.

Methods. This is a retrospective study performed by collecting consecutive cases diagnosed between January 2000 and December 2020 in five tertiary centers. Associations between STUMP recurrence and clinicopathological characteristics as well as surgical treatment modality were investigated.

Results. Eighty-seven patients affected by STUMP were considered. Of them, 18 cases (20.7%) recurred: 11 as leiomyosarcoma (LMS) and 7 as STUMP. The mean time to recurrence was 79 months. We found that fragmentation/morcellation, epithelioid features, high mitotic count, Ki-67 value > 20%, progesterone receptor (PR) < 83%, and p16 diffuse expression were associated with higher risk of recurrence and shorter recurrence-free survival (RFS). Furthermore, morcellation/fragmentation and mitotic count remained independent risk factors for recurrence and shorter RFS after multivariate analysis, while the presence of epithelioid features was an independent risk factor for recurrence only.

Conclusions. Our results suggest that morcellation is associated with risk of recurrence and shorter RFS, thus it should be avoided if a STUMP is suspected preoperatively. Epithelioid features, high proliferation activity, low PR expression, and diffuse p16 expression are also unfavorable prognostic factors, so patients presenting these features should be closely followed up.

Uterine smooth muscle tumors of uncertain malignant potential (STUMPs) are extremely rare neoplasms, and available literature is limited to small and mainly monocentric retrospective series. In 1994, Bell et al. reviewed 213 problematic uterine smooth muscle tumors (USMTs) proposing STUMP diagnostic criteria on the basis of the presence of tumor cell atypia, necrosis, and mitotic figures assessed as to their count per 10 high-
power fields (HPFs)]. In the following years, the World Health Organization (WHO) Classification of Tumors of Female Reproductive Organs defined uterine STUMP as a USMT that cannot be diagnosed unequivocally as benign or malignant and does not satisfy all the diagnostic criteria for a leiomyosarcoma (LMS). 

Some authors have also tried to identify useful tools for the preoperative diagnosis of STUMPs, but to date, none has entered clinical practice. 

Furthermore, there is no consensus about the postoperative management of these tumors. Despite these uncertainties, protocols for the management of these neoplasms would be highly warranted since recurrence is relatively frequent. Indeed, a recent review reported an overall recurrence rate of 11–13% as either STUMP or LMS, but other authors reported even higher recurrence rates, up to 36.4% in a monocentric series of 22 STUMPs. 

Identification of prognostic markers of recurrence is warranted since to date, there are no validated clinical or pathological parameters which predict the longitudinal behavior of these lesions.

The aim of this study is thus to evaluate a wide range of clinical, surgical, and pathological characteristics in a large, multicenter, patient series to identify risk factors of recurrence that could be exploited to tailor the management of these rare neoplasms.

**MATERIALS AND METHODS**

A multicenter, retrospective, cohort study was performed collecting consecutive cases diagnosed between January 2000 and December 2020 in five tertiary centers (A.O.U. Città della Salute e della Scienza, S. Anna Hospital, Turin, Italy; Mauriziano Hospital, Turin, Italy; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy; European Institute of Oncology IRCCS, Milan, Italy; Leon Berard Cancer Center, Lyon, France). We searched the archives of the Gynecological Oncology and Pathology units of each institution for all cases classified as STUMP. All samples were reviewed by two expert pathologists (I.C., L.B.) to confirm the diagnostic assessment of STUMP according to the most recent diagnostic criteria provided by the 2020 WHO Classification of Tumors of Female Reproductive Organs [i.e., USMTs not fitting the diagnostic criteria of leiomyoma or LMS: (a) absent necrosis, focal/multifocal/diffuse moderate to severe atypia, < 10 mitoses/10 HPFs; (b) presence of necrosis, none or mild atypia, < 10 mitoses/10 HPFs; and (c) absent necrosis, none atypia, > 15 mitoses/10 HPFs]. Conversely, LMS diagnosis requires the presence of two out of the three following features: marked cellular atypia, > 10 mitoses/10 HPFs, or necrosis.

The following histopathological parameters were also recorded: cellularity, grade/extension of cellular atypia, highest mitotic count per 10 HPFs, presence of atypical mitoses, presence and type of necrosis (ischemic or coagulative), presence of myxoid, epithelioid or degenerative features, apoptosis and intravascular intrusions. Immunohistochemistry stains for Ki-67, estrogen receptor (ER), progesterone receptor (PR), p16, and p53 were performed whenever possible and assessed considering the rate of positive cells.

For outcome analyses, we considered as cutoff values the mean number of mitoses (per 10 HPFs), Ki-67 proliferation index (%), and EmiR and PR positive cells (%). We also tested the prognostic significance of cutoff values of 10 mitoses/10 HPFs, and 20% Ki-67 positivity, as some authors have reported their unfavorable prognostic significance in UMSTs.

Patient data were extracted from medical records. The variables analyzed included age at diagnosis, number of previous pregnancies, menopausal status, body mass index (BMI), smoking status, surgical procedure, largest tumor diameter (mm), and presence of associated leiomyomas and/or adenomyosis in surgically resected specimens. On the basis of pathological and surgical reports, we defined fragmentation as the manual/instrumental partial fragmentation of the neoplasm within the pelvic cavity during the enucleation, and morcellation as the division and removal of the lesion in small pieces through an abdominal incision or by vaginal route. No cases of in-bag morcellation were reported.

Disease recurrence was defined as any histologically confirmed relapse as STUMP or LMS. Survival time was measured from date of surgery until last follow-up, recurrence, or death from any cause.

Owing to the retrospective nature of the study and the lack of a standard follow-up protocol for STUMPs, differences were observed among centers/patients; however, in most cases, patients underwent a gynecological and ultrasound examination every 6 months for the first 5 years after initial diagnosis and then annually. In case of suspicion of recurrence, further diagnostic examinations were performed (abdominal/chest computed tomography, and/or positron emission tomography as appropriate).

Patients with no histological confirmation at pathological review or with follow-up shorter than 6 months were excluded.

Written consent was not required considering the retrospective nature of the study. The study was conducted in accordance with the Declaration of Helsinki and was approved by our local ethical committee (protocol number 0119045).
Statistical analyses were performed using IBM SPSS version 23 (SPSS Inc., Chicago, IL) software. Differences in proportions among categorical data of patients who had a recurrence and those who had not were assessed using Pearson’s chi-squared test or Fisher’s exact test. For continuous variables, the Shapiro–Wilk test was used to test data normality, and then, the Mann–Whitney U-test was used for data comparison. Survival times were analyzed using -Kaplan–Meier curves and comparisons were performed by the log-rank test. A binary logistic regression model was performed using recurrence as the dependent variable and patient/STUMP characteristics as covariates. Multivariable logistic regression models were created by a backward stepwise procedure. The prognostic value of the variables was tested by univariate and multivariate analysis with the Cox regression model. Statistically significant values from Cox univariate analyses were entered into a multivariate Cox regression model. Statistically significant values from Cox univariate analyses were entered into a multivariate analysis using the backward stepwise Cox regression model. All the analyses were conducted with a 95% confidence interval (CI), and a two-sided p-value of 0.05 was considered statistically significant.

RESULTS

Clinical Characteristics

A total of 103 patients were initially considered. Sixteen patients with no histological confirmation at pathological review (n =12, 7 reclassified as a variant of leiomyoma, 5 as LMS) or with follow-up shorter than 6 months (n = 4) were excluded. Finally, 87 patients with a confirmed diagnosis of STUMP were included in the study (Table 1).

The mean age at diagnosis was 46 (standard deviation (SD) 10, range 19–82) years, the most frequent ethnicity was Caucasian (83 of 87, 95% of patients), and the mean follow-up was 67 (SD ± 65, range 6–256) months.

The mean BMI was 25 (SD 4, range 19–40, 20 missing data), 51 of 79 patients (65%, 8 missing data) had previous pregnancies, 11 of 74 were smokers (15%, 13 missing data), and 65 of 85 (76%, 2 missing data) were symptomatic at the time of diagnosis.

Detailed data regarding the surgical procedures were collected. Most patients underwent hysterectomy (59 of 87, 68% of patients), while a laparoscopic approach was performed in only 12 of 87 (14%) patients.

In 28 of 87 (32%) cases, the tumor was morcellated or fragmented intraoperatively. In 12 of 28 (43%) patients who initially underwent a myomectomy, a hysterectomy was performed after the histological diagnosis of STUMP.

All STUMPs were confined to the uterine body at the time of first surgery, with a mean largest dimension of 73 (SD 44, range 5–230) mm.

Histopathological Features

STUMP histopathological features were comprehensively analyzed. Moderate or severe cytological atypia was observed in 28 of 87 (68%) cases and diffuse cytological atypia in 27 of 87 (33%). Necrosis was observed in 34 of 87 (39%) cases; in 24 (71%) samples, the findings were consistent with ischemic necrosis, and in 10 (29%) with coagulative necrosis. High cellularity was observed in about half of the STUMPs (42 of 87, 48% of cases), and apoptotic figures in 26 of 87 (30%) cases. Other histopathological features (epithelioid or myxoid patterns, degenerative features, and the presence of atypical mitosis and/or vascular intrusions) were rarely present.

The mean value of mitoses/10 HPFs was 6 (SD 7, range 1–43) and cases with a mitotic count/10 HPFs ≥ 6 and > 10 were 35 (40%) and 13 (15%), respectively.

The mean Ki-67 value (10 missing data) was 16% (SD 15%, range 1–80%), while a Ki-67 value > 20% was observed in 15 of 77 (20%) cases. Mean ER- and PR-positive cells were 72% (21 missing data, SD ± 20, range 5–100%) and 83% (21 missing data, SD 18%, range 0–100%), respectively. ER expression < 72% was observed in 32 of 66 (48%) cases, and PR expression < 83% in 19 of 66 (29%) STUMPs. Finally, p53 and p16 were found to be expressed in 16 of 57 (30 missing data, 28%) and 19 of 47 (40 missing data, 40%) cases.

Associated leiomyomas and/or adenomyosis were reported in 46 of 86 (1 missing data, 54%) and 11 of 86 (1 missing data, 13%) of the surgical specimens, respectively.

Outcome Analysis

Overall, 18 (20.7%) cases recurred: 11 as LMS (12%) and 7 as STUMP (7.8%). The mean time to recurrence was 79 (SD 55, range 10–174) months. Of the 18 STUMPs that recurred, 5 (5.7%) patients died because of this disease [disease-specific survival (DSS): 94.3%].

No significant differences were observed between patients with and without disease recurrence in terms of age, number of previous pregnancies, BMI, type of symptoms, menopausal, and smoking status.

Although recurrence rates were not different according to the specific surgical procedure or approach, more recurrences were observed after intraoperative tumor fragmentation/morcellation (p = 0.003).

The following histopathological and immunohistochemical features showed a significantly different distribution according to recurrence: (a) presence of epithelioid features (p = 0.009), (b) higher mitotic count/10 HPFs (p = 0.01), (c) mitotic count ≥ 6/10 HPFs (mean value of mitotic count in the whole series) (p = 0.042) and > 10 per 10 HPFs (p = 0.004), (d) Ki-67 value > 20% (p =
| Clinical characteristic          | STUMP samples, n (%) |
|---------------------------------|----------------------|
| Ethnicity                       |                      |
| Caucasian                       | 83 (95%)             |
| Non-Caucasian                   | 4 (5%)               |
| Mean age (years) SD (range)     | 46 ± 10 (19–82)      |
| Age (years)                     |                      |
| < 46                            | 40 (46%)             |
| ≥ 46                            | 47 (54%)             |
| Number of pregnancies (NA 8)    |                      |
| 0                               | 28 (35%)             |
| ≥ 1                             | 51 (65%)             |
| Menopause (NA 1)                |                      |
| No                              | 72 (84%)             |
| Yes                             | 14 (16%)             |
| Mean BMI (SD, range)            | 25 ± 4 (19–40)       |
| Smoking (NA 13)                 |                      |
| No                              | 63 (85%)             |
| Yes                             | 11 (15%)             |
| Abnormal uterine bleeding (NA 2)|                      |
| No                              | 20 (24%)             |
| Yes                             | 65 (76%)             |
| Pelvic pain (NA 2)              |                      |
| No                              | 62 (73%)             |
| Yes                             | 23 (27%)             |
| Abdominal bloating (NA 2)       |                      |
| No                              | 69 (81%)             |
| Yes                             | 16 (19%)             |
| Surgical procedure              |                      |
| Hysterectomy                    | 59 (68%)             |
| Myomectomy                      | 28 (32%)             |
| Surgical approach               |                      |
| Laparotomy                      | 70 (80%)             |
| Vaginal                         | 4 (5%)               |
| Laparoscopy                     | 13 (15%)             |
| Fragmentation/morcellation      |                      |
| No                              | 59 (68%)             |
| Yes                             | 28 (32%)             |
| Surgical procedure (without fragmentation/morcellation) | |
| Hysterectomy                    | 43 (73%)             |
| Myomectomy                      | 16 (27%)             |
| Mean maximum diameter (mm) (NA = 7) SD (range) | 73 ± 44 (5–230) |

**Histological features**

| Associated leiomyomas (NA 1) | STUMP samples, n (%) |
|------------------------------|----------------------|
| No                           | 40 (46%)             |
| Yes                          | 46 (54%)             |

**Table 1 (continued)**

| Associated adenomyosis (NA 1) | STUMP samples, n (%) |
|-------------------------------|----------------------|
| No                            | 75 (87%)             |
| Yes                           | 11 (13%)             |
| Atypia (severity)             |                      |
| Absent/mild                   | 59 (68%)             |
| Moderate/severe               | 28 (32%)             |
| Atypia (extension)            |                      |
| Focal                         | 60 (67%)             |
| Diffuse                       | 27 (33%)             |
| Necrosis                      |                      |
| No                            | 53 (61%)             |
| Yes                           | 34 (39%)             |
| Ischemic                      | 24 (71%)             |
| Coagulative                   | 10 (29%)             |
| Hypercellularity              |                      |
| No                            | 45 (52%)             |
| Yes                           | 42 (48%)             |
| Epithelioid features          |                      |
| No                            | 76 (87%)             |
| Yes                           | 11 (13%)             |
| Myxoid features               |                      |
| No                            | 82 (94%)             |
| Yes                           | 5 (6%)               |
| Degenerative features         |                      |
| No                            | 72 (83%)             |
| Yes                           | 15 (17%)             |
| Atypical mitosis              |                      |
| No                            | 81 (93%)             |
| Yes                           | 6 (7%)               |
| Apoptosis                     |                      |
| No                            | 61 (70%)             |
| Yes                           | 26 (30%)             |
| Vascular intrusion            |                      |
| No                            | 83 (95%)             |
| Yes                           | 4 (5%)               |
| Mean number of mitoses/10 HPFs SD (range) | 6 ± 7 (1–43) |
| Number of mitoses (according to the mean value) | |
| < 6                           | 52 (60%)             |
| ≥ 6                           | 35 (40%)             |
| Number of mitoses (cutoff: 10/10 HPFs) | |
| ≤ 10                          | 74 (85%)             |
| > 10                          | 13 (15%)             |
| Mean Ki-67 expression (%) SD (range) (NA = 10) | 16 ± 15 (1–80) |
| Ki-67 (cutoff 16%) (according to the mean value) (NA = 10) | |
| ≤ 16%                         | 54 (70%)             |
| > 16%                         | 23 (30%)             |
(e) lower PR expression \((p = 0.048)\), (f) PR expression \(\leq 83\%\) (mean value of PR expression in the whole series) \((p = 0.036)\), and (g) diffuse p16 expression \((p = 0.01)\).

Distribution of all clinical and histopathological characteristics according to recurrence is presented in Table 2.

Logistic regression univariate analysis showed an association between multiple variables and recurrence (Table 3). Multivariate logistic regression showed that STUMP morcellation/fragmentation \((OR 6.17, 95\% CI 1.707–22.32, p = 0.006)\), mitotic count \(> 10/10 HPFs\) (OR 4.78, 95\% CI 1.05–21.7, \(p = 0.043)\), and epithelioid features \((OR 4.26, 95\% CI 1.028–17.63, p = 0.046)\) were independent predictors of recurrence.

Univariate Cox regression analysis (Table 4) showed that surgical fragmentation/morcellation \((HR 3.68, 95\% CI 1.42–9.54, p = 0.007)\), epithelioid features \((HR 3.14, 95\% CI 1.17–8.40, p = 0.022)\), higher mitotic count \((HR 1.04, 95\% CI 1.005–1.084, p = 0.03)\), presence of \(> 10\) mitoses/10 HPFs \((HR 2.84, 95\% CI 1.10–5.19, p = 0.04)\), higher Ki-67 proliferation index \((HR 1.033, 95\% CI 1.009–1.057, p = 0.006)\), Ki67 > 20 \((HR 3.06, 95\% CI 1.07–8.73, p = 0.06)\), PR expression \(< 83\%\) \((HR 4.15, 95\% CI 1.47–11.7, p = 0.007)\), and diffuse p16 expression \((HR 13.1, 95\% CI 1.56–11.7, p = 0.08)\) were associated with shorter RFS.
All the variables found to be significant in the univariate analysis also had an impact on recurrence-free survival (RFS) as calculated by the Kaplan–Meier method (Fig. 1). By multivariate Cox analysis, morcellation/fragmentation (HR 5.65, 95% CI 1.53–20.8, \( p = 0.009 \)) and mitotic count considered as a linear variable (HR 1.073, 95% CI 1.019–1.130, \( p = 0.008 \)) were confirmed to be independently associated with RFS.

**DISCUSSION**

We comprehensively evaluated a wide range of clinical, surgical, and pathological features to ascertain their association with recurrence risk in STUMPs.

### Surgical Outcomes

Concerning clinical and surgical variables, the main finding of the present study is the association between morcellation/fragmentation and the risk of recurrence/shorter RFS. Overall, the optimal surgical approach to remove STUMP is a topic of debate given that there is no clear evidence whether surgical radicality offers a survival advantage; moreover, STUMPs can also occur during the

---

**Table 2 (continued)**

| Clinical and Histopathological Predictors | No recurrence \( (n = 69) \) | Recurrence \( (n = 18) \) | \( p \)-value |
|------------------------------------------|-------------------------------|------------------------|--------------|
| **Yes** | 37 (80%) | 9 (20%) | 0.44 |
| **Associated adenomyosis (NA 1)** | 58 (78%) | 17 (22%) | 0.44 |
| **Atypia (severity)** | 47 (78%) | 12 (22%) | 0.87 |
| **Atypia (extension)** | 48 (80%) | 12 (20%) | 0.81 |
| **Necrosis** | 43 (81%) | 10 (19%) | 0.60 |
| **Epithelioid features** | 64 (84%) | 12 (16%) | 0.009 |
| **Myxoid features** | 66 (80%) | 16 (20%) | 0.27 |
| **Degenerative features** | 57 (79%) | 15 (21%) | 1.00 |
| **Atypical mitosis** | 65 (80%) | 16 (20%) | 0.59 |
| **Apoptosis** | 49 (80%) | 12 (20%) | 0.72 |
| **Vascular intrusion** | 66 (80%) | 17 (20%) | 1.00 |
| **Mean number of mitoses/10 HPFs SD (range)** | 4.5 ± 4 (1–18) | 11 ± 11 (1–43) | 0.01 |
| **Number of mitoses (according to the mean value)** | 45 (86%) | 7 (14%) | 0.042 |
| 6 | 24 (69%) | 11 (31%) | |
| **Number of mitoses (cutoff 10/10 HPFs)** | 61 (82%) | 10 (18%) | 0.004 |
| > 10 | 8 (62%) | 8 (38%) | |
| **Mean Ki-67 expression (%) SD (range) (NA = 10)** | 13 ± 12 (1–70) | 25 ± 23 (1–80) | 0.007 |
| **Ki-67 (cutoff 20%) (NA = 10) (according to the mean value)** | 45 (83%) | 9 (17%) | 0.17 |

**BMI** body mass index, **ER** estrogen receptor, **NA** not available, **PR** progesterone receptor, **SD** standard deviation, **STUMP** smooth muscle tumors of uncertain malignant potential.
### TABLE 3

Univariate analysis of clinicopathological variables associated with disease recurrence (in bold significant p-values)

| Variable                          | Univariate analysis OR (95% CI) | p-value |
|-----------------------------------|---------------------------------|---------|
| Ethnicity                         |                                 |         |
| Caucasian                         | 1                               | 0.43    |
| Non-Caucasian                     | 0.06 (0.00–1.43)                |         |
| Age (years)                       | 1.018 (0.97–1.07)               | 0.49    |
| Age < 45 years                    |                                 |         |
| < 45                              | 1                               | 0.36    |
| ≥ 45                              | 1.62 (0.57–4.61)                |         |
| Number of pregnancies             |                                 |         |
| 0                                 | 1                               | 0.11    |
| ≥ 1                               | 0.39 (0.13–1.24)                |         |
| Menopause                         |                                 |         |
| No                                | 1                               | 0.14    |
| Yes                               | 2.52 (0.72–8.77)                |         |
| BMI                               | 0.94 (0.78–1.12)                | 0.49    |
| Smoking                           |                                 |         |
| No                                | 1                               | 0.61    |
| Yes                               | 2.70 (0.67–10.8)                |         |
| Abnormal uterine bleeding         |                                 |         |
| No                                | 1                               | 0.98    |
| Yes                               | 1.01 (0.36–2.88)                |         |
| Pelvic pain                       |                                 |         |
| No                                | 1                               | 0.50    |
| Yes                               | 1.41 (0.48–4.52)                |         |
| Abdominal bloating                |                                 |         |
| No                                | 1                               | 0.79    |
| Yes                               | 0.83 (0.21–3.30)                |         |
| Surgical procedure                |                                 |         |
| Hysterectomy                      | 1                               | 0.77    |
| Myomectomy                        | 0.78 (0.24–2.42)                |         |
| Surgical approach                 |                                 |         |
| Laparotomy                        | 1                               | 0.74    |
| Vaginal                           | 1.59 (0.43–5.81)                | 0.24    |
| Laparoscopy                       | 1.49 (0.14–15.46)               |         |
| Fragmentation/morcellation        |                                 |         |
| No                                | 1                               | 0.005   |
| Yes                               | 4.80 (1.60–14.4)                |         |
| Surgical procedure (without fragmentation/morcellation) | | |
| Hysterectomy                      | 1                               | 0.92    |
| Myomectomy                        | 1.08 (0.18–6.25)                |         |
| Diameter (mm)                     | 1.00 (0.99–1.01)                | 0.94    |
| Associated leiomyomas             |                                 |         |
| No                                | 1                               | 0.74    |
| Yes                               | 0.83 (0.29–2.36)                |         |
| Associated adenomyosis            |                                 |         |
| No                                | 1                               | 0.34    |
| Yes                               | 0.34 (0.04–2.55)                |         |
| Cellular atypia                   |                                 |         |

### Table 3 (continued)

| Variable                          | Univariate analysis OR (95% CI) | p-value |
|-----------------------------------|---------------------------------|---------|
| Absent/mild                       | 1                               | 0.83    |
| Moderate/severe                   | 1.12 (0.38–3.25)                |         |
| Focal                             | 1                               | 0.81    |
| Diffuse                           | 1.14 (0.38–3.45)                |         |
| Necrosis                          |                                 |         |
| No                                | 1                               |         |
| Yes                               | 1.32 (0.46–3.77)                | 0.16    |
| Ischemic                          | 1                               |         |
| Coagulative                       | 3.33 (0.63–17.5)                |         |
| Hypercellularity                  |                                 |         |
| No                                | 1                               | 0.22    |
| Yes                               | 1.92 (0.67–5.55)                |         |
| Epithelioid features              |                                 |         |
| No                                | 1                               | 0.007   |
| Yes                               | 6.4 (1.68–24.37)                |         |
| Myxoid features                   |                                 |         |
| No                                | 1                               | 0.29    |
| Yes                               | 2.75 (0.42–17.8)                |         |
| Degenerative features             |                                 |         |
| No                                | 1                               | 0.94    |
| Yes                               | 0.95 (0.24–3.80)                |         |
| Atypical mitoses                  |                                 |         |
| No                                | 1                               | 0.44    |
| Yes                               | 2.03 (0.34–3.86)                |         |
| Apoptosis                         |                                 |         |
| No                                | 1                               | 0.72    |
| Yes                               | 1.22 (0.40–3.71)                |         |
| Vascular intrusion                |                                 |         |
| No                                | 1                               | 0.82    |
| Yes                               | 1.29 (0.13–13.2)                |         |
| Number of mitoses/10 HPFs         | 1.14 (1.04–1.24)                | 0.006   |
| Number of mitoses/10 HPFs < 6     | 1                               | 0.04    |
| ≥ 6                               | 2.93 (1.01–8.58)                | 0.03    |
| ≤ 10                              | 1                               |         |
| > 10                              | 2.94 (1.09–10.4)                |         |
| Ki-67 expression                  | 1.04 (1.007–1.08)               | 0.017   |
| Ki-67 (cutoff 16%)                 |                                 |         |
| < 16%                             | 1                               | 0.18    |
| ≥ 16%                             | 2.19 (0.70–6.84)                |         |
| Ki-67 (cutoff 20%)                 |                                 |         |
| ≤ 20%                             | 1                               | 0.048   |
| > 20%                             | 3.46 (1.008–11.9)               |         |
| ER expression                     | 0.99 (0.96–1.02)                | 0.55    |
| ER expression (cutoff 72%)        |                                 |         |
| ≥ 72%                             | 1                               | 0.89    |
| < 72%                             | 1.08 (0.35–3.34)                |         |
The Food and Drug Administration (FDA) and the results reported by other authors. The same was not true for morcellation: recurrences were significantly more frequent after any type of morcellation (power or hand morcellation). This finding strongly supports the limited evidence available so far suggesting this association. In a small study on seven patients with a diagnosis of STUMP or endometrial stromal sarcoma who underwent power or hand morcellation during hysterectomy or myomectomy, six cases of recurrence were observed after surgical reexploration. Interestingly, a relapse was also seen in a case using a contained bag system. A recent study on 152 patients affected by early-stage uterine LMS also showed that any type of morcellation is related to risk of recurrence. Furthermore, in a retrospective multicenter study on 125 patients affected by uterine sarcomas or STUMPs, women undergoing either morcellation or power morcellation experienced a three-fold increase in the risk of death in comparison with patients who had not (p = 0.02), and a trend toward an increase of risk for recurrence was specifically found in the limited series (n = 11) of women undergoing morcellation for STUMP (HR 7.7, p = 0.09). The Food and Drug Administration (FDA) and the American College of Obstetricians and Gynecologists (ACOG) stated that morcellation should be avoided in patients over the age of 50 years, while for younger patients the possibility of a minimally invasive surgery should be carefully considered weighing the risk–benefit ratio. In this context, in-bag morcellation could reduce or nullify the risk of recurrence; however, solid evidence is lacking.

Our data support that morcellation/fragmentation should not be performed if a STUMP is suspected and, if performed, close follow-up is advised.

### Histopathological Features

Histopathological classification of STUMPs represents a diagnostic gray area between leiomyomas and LMSs. To tackle this unmet diagnostic need, we evaluated the prognostic significance of several histological features potentially related to more aggressive tumor biology. The presence of epithelioid features and a higher mitotic count were found to be significant predictors of recurrence, while cellular atypia, which is included in STUMP diagnostic criteria, was not, similarly to other authors’ findings. STUMPs frequently show high cellularity; however, this finding also lacks correlation with outcomes as observed in our study. The presence of necrosis is a common feature of LMS; however, it can also be detected in STUMPs partly owing to tissue ischemia.

Gupta et al. suggested that atypical mitoses, epithelioid differentiation, and vascular intrusion are possible predictors of recurrence. In the present series, we found higher recurrence rates and shorter RFSs in cases with epithelioid differentiation. In line with this observation, this feature was found to be related to more aggressive biological behaviors in studies analyzing the whole USMT spectrum. Myxoid features, another rare morphological trait that can mimic the inflammatory myofibroblastic tumor, did not correlate with worse outcomes.

Proliferation activity and mitotic count represent well-recognized prognostic markers of most soft tissue tumors; however, their significance in STUMPs is another controversial issue. In two previous studies, the mitotic count did not result as a significant prognostic parameter, while Ip et al. observed a trend toward lower mitotic counts in nonrecurring cases. Huo et al. proposed a cutoff of > 10 mitoses per 10 HPFs as a risk factor for recurrence, a finding confirmed by our study on multivariate analysis (although no association with RFS was observed). Finally, it should be noted that, in USMTs, the mitotic count has to be considered together with other histopathological features to correctly distinguish STUMPs from mitotically active leiomyomas and LMSs.

Ki-67 expression is routinely evaluated in many neoplasms as a measure of proliferation activity, and in some cases, such as human epidermal growth factor receptor 2 (HER2)-negative luminal breast cancers, it can be used to...
| Variable | Univariate analysis | HR (95% CI) | p-Value |
|----------|-------------------|-------------|---------|
| Ethnicity |                   |             |         |
| Caucasian | 1                 | 0.43        |         |
| Non-Caucasian | 0.043 (0.00–5.43) |             |         |
| Age (years) | 1.017 (0.97–1.067) | 0.49       |         |
| Age < 45 years |                   |             |         |
| < 45 | 1                 | 0.42        |         |
| ≥ 45 | 1.47 (0.57–3.77)   |             |         |
| Number of pregnancies |             |             |         |
| 0 | 1                 |             |         |
| ≥ 1 | 0.53 (0.20–1.45)   | 0.217       |         |
| Menopause |                   |             |         |
| No | 1                 | 0.10        |         |
| Yes | 2.36 (0.84–6.67)   |             |         |
| BMI | 0.95 (0.80–1.12)   | 0.55        |         |
| Smoking |                   |             |         |
| No | 1                 | 0.10        |         |
| Yes | 2.57 (0.82–8.17)   |             |         |
| Abnormal uterine bleeding |             |             |         |
| No | 1                 | 0.90        |         |
| Yes | 1.04 (0.41–2.64)   |             |         |
| Pelvic pain |               |             |         |
| No | 1                 | 0.48        |         |
| Yes | 1.42 (0.53–3.79)   |             |         |
| Abdominal bloating |             |             |         |
| No | 1                 | 0.82        |         |
| Yes | 1.15 (0.33–4.09)   |             |         |
| Surgical procedure |             |             |         |
| Hysterectomy | 1               | 0.92        |         |
| Myomectomy | 0.95 (0.34–2.70)  |             |         |
| Surgical approach |             |             |         |
| Laparotomy | 1                | 0.91        |         |
| Vaginal | 1.87 (0.20–16.7)   | 0.58        |         |
| Laparoscopy | 0.89 (0.12–6.88)  |             |         |
| Fragmentation/morcellation |             |             |         |
| No | 1                 | 3.68 (1.42–9.54) | 0.007 |
| Yes |             |             |         |
| Surgical procedure (without fragmentation/morcellation) |             |             |         |
| Hysterectomy | 1               | 0.89        |         |
| Myomectomy | 1.12 (0.2–5.8)    |             |         |
| Diameter (mm) | 1.006 (0.99–1.02) | 0.30       |         |
| Associated leiomyomas |             |             |         |
| No | 1                 | 0.77        |         |
| Yes | 0.87 (0.34–2.20)   |             |         |
| Associated adenomyosis |             |             |         |
| No | 1                 | 0.30        |         |
| Yes | 0.30 (0.04–2.29)   |             |         |

### Table 4 (continued)

| Variable | Univariate analysis | HR (95% CI) | p-Value |
|----------|-------------------|-------------|---------|
| Cellular atypia |                   |             |         |
| Absent/mild | 1               |             |         |
| Moderate/severe | 0.57 (0.21–1.50) |             |         |
| Focal | 1                 |             |         |
| Diffuse | 1.11 (0.41–2.98)   |             |         |
| Necrosis |                   |             |         |
| No | 1                 | 0.40        |         |
| Yes | 1.49 (0.58–3.82)   |             |         |
| Ischemic | 1                |             |         |
| Coagulative | 1.86 (0.46–7.54)  |             |         |
| Hypermaturity |                   |             |         |
| No | 1                 | 0.67        |         |
| Yes | 1.24 (0.47–3.23)   |             |         |
| Epithelioid features |             |             |         |
| No | 1                 |             |         |
| Yes | 3.14 (1.17–8.40)   | 0.022       |         |
| Myxoid features |             |             |         |
| No | 1                 | 0.64        |         |
| Yes | 1.42 (0.32–6.21)   |             |         |
| Degenerative features |             |             |         |
| No | 1                 | 0.89        |         |
| Yes | 0.89 (0.25–3.07)   |             |         |
| Atypical mitoses |             |             |         |
| No | 1                 | 0.20        |         |
| Yes | 2.59 (0.58–11.4)   |             |         |
| Apoptosis |               |             |         |
| No | 1                 | 0.20        |         |
| Yes | 0.51 (0.17–1.44)   |             |         |
| Vascular intrusion |             |             |         |
| No | 1                 | 0.63        |         |
| Yes | 1.60 (0.21–12.3)   |             |         |
| Number of mitoses/10 HPFs |             |             |         |
| < 6 | 1                 |             | 0.07    |
| ≥ 6 | 2.40 (0.92–6.23)   |             |         |
| ≤ 10 | 1                |             | 0.04    |
| > 10 | 2.84 (1.10–5.19)   |             |         |
| Ki-67 expression |             |             |         |
| < 16% | 1                |             | 0.121   |
| ≥ 16% | 2.23 (0.80–6.18)   |             |         |
| Ki-67 (cutoff 16%) |             |             |         |
| < 16% | 1                |             | 0.036   |
| ≥ 16% | 3.06 (1.07–8.73)   |             |         |
| ER expression |             |             |         |
| < 72% | 1                | 0.80        |         |
| > 72% | 0.998 (0.97–1.02)  |             |         |
| ER expression (cutoff 72%) |             |             |         |
identify which patients shall be treated with adjuvant chemotherapy. However, the usefulness of Ki-67 for USMTs is controversial. O’Neill et al. compared Ki-67 expression between 22 LMS and 41 other USMTs: 19 of 22 LMS showed a Ki-67 proliferation index ≥ 20%, while all other USMTs had a Ki-67 proliferation index < 20%; however, the sample size of STUMPs in this study was remarkably low (only 4 cases). Mayerhofer et al. compared Ki-67 rates of 25 leiomyomas, 22 STUMPs, and 20 LMS: no STUMP showed an elevated Ki-67 expression; however, no recurrence was reported among these cases. Although methodological differences are present between the different studies (e.g., antibody used and counting method), available data suggest a higher expression of Ki-67 in LMS as expected; however, STUMPs are poorly represented and Ki-67 usefulness to predict their recurrence has been poorly explored so far. A recent meta-analysis suggested that Ki-67 is not useful to predict STUMP recurrence; however, only 5 monocentric cohorts were analyzed in this study with a total sample size of 107 STUMPs and 15 recurrences only. Moreover, the authors provided data regarding a single Ki-67 cutoff value (10%), while our results suggest that a cutoff value of 20% is related to both recurrence and shorter RFS at univariate analysis.

The impact of hormone receptors (ER and PR) has been extensively studied in breast cancer and in different gynecological tumors, observing an association between their higher expression and better prognosis. In the present study, we detected, through univariate analysis, an association between lower expression of PR and a higher risk of relapse. Interestingly, a lower expression of PR is associated with worse prognosis in stage I LMS.

Finally, we studied the potential role of p16 and p53 expressions. Alterations of these oncosuppressor proteins have been documented in STUMPs and LMSs. Some authors also suggested a predictive role, in terms of disease recurrence, of both p16 and p53 immunohistochemical expression, a finding confirmed by a recent systematic review and meta-analysis of literature. Nevertheless, the experience with these markers is still limited, and their evaluation is not recommended in clinical practice. We also found a potential relationship between diffuse p16 expression and risk of recurrence.

More recently, approaches based on molecular profiling have been proposed to improve STUMP stratification into benign and malignant lesions. Croce et al. analyzed the genomic profile of a series of different USMTs (24 STUMPs, 10 LMSs, and 10 leiomyomas) by array comparative genomic hybridization to evaluate the prognostic significance of genomic alterations (i.e., genomic index). These authors found that a specific genomic index threshold (index = 10) divides the STUMP category into two groups of neoplasms with different outcomes: a group comparable with leiomyomas and another similar to LMS, but with more indolent behavior. The same authors suggest that USMTs classified as stage I molecular LMS with 13q loss including RB1 and 17p gain including MYOCD gain are characterized by a worse prognosis. In another study, an array CGH analysis was performed on 23 USMTs (14 STUMPs, 5 LMSs, 3 leiomyomas, and 1 undifferentiated sarcoma), suggesting that the PRKDC and PUM2 genes may have a prognostic role. However, the number of STUMPs analyzed within these studies is relatively low, thus these findings should be validated/standardized on larger case series, and it should be noted that, to date, these approaches are not considered as diagnostic criteria according to the most recent diagnostic WHO classification.

Survival Outcomes

In this study, we reported a RFS and a DSS for STUMPs of 79.3% and 94.3%, respectively. A recent review reported a lower recurrence rate range (8.7–11%), similar to those reported by Gadducci et al. These values are lower compared with our study, but Gupta et al. reported a significantly higher recurrence rate (36.4%) in a series of 22 STUMPs, suggesting that some variations are present

| Variable | Univariate analysis HR (95% CI) | p-Value |
|----------|---------------------------------|---------|
| ≥ 72%    | 1                               | 0.56    |
| < 72%    | 1.34 (0.50–3.61)                |         |
| PR expression | 0.97 (0.95–0.99) | **0.003** |
| PR (cutoff 83%) |                             |         |
| ≥ 83%    | 1                               | **0.007** |
| < 83%    | 4.15 (1.47–11.7)               |         |
| p53 expression |                             |         |
| Negative | 1                               | 0.10    |
| Positive | 3.20 (0.80–11.4)               |         |
| p16 expression |                             |         |
| Absent/focal | 1                          | **0.018** |
| Widespread | 13.1 (1.56–111.7)              |         |

**BMI** body mass index, CI confidence interval, ER estrogen receptor, HR hazard ratio, NA not available, PR progesterone receptor, SD standard deviation, STUMP smooth muscle tumors of uncertain malignant potential.
among neoplasms presently classified as STUMPs according to current diagnostic criteria. With our results, we propose new histopathological parameters that could be useful for discriminating high-risk from low-risk STUMPs; however, they remain a clearly distinct entity compared with LMS since the latter show significantly higher recurrence rates (45–75%) and poor 5-year survival rates (25–75%) compared with STUMPs (92–100%).

**Strength and Limitations**

The main limitations of this study are related to its retrospective nature, and to the potential differences in terms of patients’ management due to the lack of guidelines. Nevertheless, this study is, to the best of the authors’ knowledge, the largest multicenter series investigating STUMPs recurrence, and all samples and data were obtained and reviewed within tertiary referral centers with expert pathologists and clinicians.
CONCLUSIONS

Focusing on surgical management, our results stress the importance of avoiding any type of morcellation in case of preoperative suspicion of STUMP and recommend careful follow-up in this subset of patients, while the surgical procedure and approach do not appear to be related to greater risk of recurrence. Pathological characteristics, epithelioid features, high proliferation activity, low PR expression, and diffuse p16 expression resulted associated with disease recurrence and shorter RFS.

Our data support the current classification of STUMPs as an entity different from classic LMSs. The identified variables can help distinguish a subset of cases with higher risk of recurrence that could represent a subgroup of low-grade LMS.6

FUNDING Open access funding provided by Università degli Studi di Torino within the CRUI-CARE Agreement. The present study was supported by grants from Rete Oncologica del Piemonte e Valle d’Aosta and Fondazione Cassa di Risparmio di Torino (File Number: 2021.0553).

DISCLOSURES The authors declare that they have no conflicts of interest.

OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

REFERENCES

1. Ip PPC, Cheung ANY, Clement PB. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases. Am J Surg Pathol. 2009;33(7):992–1005. https://doi.org/10.1097/PAS.0b013e3181a02d4c.
2. Guntupalli SR, Ramirez PT, Anderson ML, Milam MR, Bodurka DC, Malpica A. Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis. Gynecol Oncol. 2009;113(3):324–6. https://doi.org/10.1016/j.ygyno.2009.02.020.
3. Ng JSY, Han A, Chew SH, Low J. A clinicopathologic study of uterine smooth muscle tumors of uncertain malignant potential (STUMP). Ann Acad Med Singap. 2010;39(6):625–8.
4. Dańška-Bidzińska A, Bakula-Zalewska E, Nasierowska-Guttmejer A, et al. Smooth muscle tumor of uncertain malignant potential (STUMP)—clinicopathomorphological analysis of the cases and literature review. Ginekol Pol. 2012;83(6):412–6.
5. Dall’Asta A, Gizzo S, Musaró A, et al. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): pathology, follow-up and recurrence. Int J Clin Exp Pathol. 2014;7(11):8136–42.
6. Bacanagkil BH, Deveci M, Karabuk E, Soyman Z. Uterine smooth muscle tumor of uncertain malignant potential: clinicopathologic-sonographic characteristics, follow-up and recurrence. World J Oncol. 2017;8(3):76–80. https://doi.org/10.14740/wjou1031w.
7. Basaran D, Usbubutun A, Salman MC, et al. The clinicopathological study of 21 cases with uterine smooth muscle tumors of uncertain malignant potential: centralized review can purify the diagnosis. Int J Gynecol Cancer. 2018;28(2):233–40. https://doi.org/10.1097/IGC.0000000000001178.
8. Gupta M, Laury AL, Nucci MR, Quade BJ. Predictors of adverse outcome in uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathological analysis of 22 cases with a proposal for the inclusion of additional histological parameters. Histopathology. 2018;73(2):284–98. https://doi.org/10.1111/his.13515.
9. Şahin H, Karatas F, Coban G, et al. Uterine smooth muscle tumor of uncertain malignant potential: fertility and clinical outcomes. J Gynecol Oncol. 2019;30(4):e54. https://doi.org/10.3802/jgo.2019.30.4.e54.
10. Huo L, Wang D, Wang W, et al. Oncologic and reproductive outcomes of uterine smooth muscle tumor of uncertain malignant potential: a single center retrospective study of 67 cases. Front Oncol. 2020;10:647. https://doi.org/10.3389/fonc.2020.00647.
11. Shim JJ, Han AKW, Jeon HJ, et al. Clinical experience of uterine smooth muscle tumor of uncertain malignant potential in two gynecological centers: oncological and obstetric aspects. Eur J Obstet Gynecol Reprod Biol. 2020;246:7–13. https://doi.org/10.1016/j.ejogrb.2020.01.002.
12. Zheng YY, Liu XB, Mao YY, Lin MH. Smooth muscle tumor of uncertain malignant potential (STUMP): a clinicopathologic analysis of 26 cases. Int J Clin Exp Pathol. 2020;13(4):818–26.
13 Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms: A clinicopathologic study of 213 cases. Am J Surg Pathol. 1994;18(6):535–58.
14. Smooth muscle tumour of uncertain malignant potential of the uterine corpus, In WHO Classification of Tumours Editorial Board (Eds.), WHO Classification of Tumours, 5th Edition, Female Genital Tumours, n. 279–280. Lyon: International Agency for Research on Cancer, 2020.
15. Cotrino I, Carosso A, Macchi C, et al. Ultrasound and clinical characteristics of uterine smooth muscle tumors of uncertain malignant potential (STUMPs). Eur J Obstet Gynecol Reprod Biol. 2020;251:167–72. https://doi.org/10.1016/j.ejogrb.2020.05.040.
16. Gadducci A, Zannoni GF. Uterine smooth muscle tumors of unknown malignant potential: a challenging question. Gynecol Oncol. 2019;154(3):631–7. https://doi.org/10.1016/j.ygyno.2019.07.002.
17. O’Neill CJ, McBride HA, Connolly LE, McCluggage WG. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumors of uncertain malignant potential. Histopathology. 2007;50(7):851–8. https://doi.org/10.1111/j.1365-2559.2007.02699.x.
18. Vilos GA, Marks J, Ettler HC, Vilos AG, Prefontaine M, Abu-Rafea B. Uterine smooth muscle tumors of uncertain malignant potential: diagnostic challenges and therapeutic dilemmas: Report of 2 cases and review of the literature. J Minim Invasive Gynecol. 2012;19(3):288–95. https://doi.org/10.1016/j.jmig.2011.12.025.
19. Mowers EL, Skinner B, McLean K, Reynolds RK. Effects of morcellation of uterine smooth muscle tumor of uncertain
malignant potential and endometrial stromal sarcoma: case series and recommendations for clinical practice. *J Minim Invasive Gynecol.* 2015;22(4):601–6. https://doi.org/10.1016/j.jmig.2015.01.007.

20. PedraNobre S, Hensley ML, So M, et al. The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome. *Gynecol Oncol.* 2021;160(1):99–105. https://doi.org/10.1016/j.ygyno.2020.10.020.

21. Raspagliesi F, Maltese G, Bogani G, et al. Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: a retrospective MITO group study. *Gynecol Oncol.* 2017;144(1):90–5. https://doi.org/10.1016/j.ygyno.2016.11.002.

22. U.S. Food and Drug Administration. Update: perform only contained morcellation when laparoscopic power morcellation is appropriate. FDA Safety Communication. Silver Spring, MD: FDA; 2020. Available at: https://www.fda.gov/medical-devices/safety-communications/update-perform-only-contained-morcellation-when-laparoscopic-power-morcellation-appropriate-fda.

23. American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice. Uterine morcellation for presumed leiomyomas: ACOG Committee Opinion, Number 822. *Obstet Gynecol.* 2021;137(3):e63–e74. https://doi.org/10.1097/AOG.0000000000004291.

24. Zullo F, Venturella R, Raffone A, Saccoone G. In-bag manual versus uncontained power morcellation for laparoscopic myomectomy. *Cochrane Database Syst Rev.* 2020;5:CD013352. https://doi.org/10.1002/14651858.CD013352.pub2.

25. Karataslı V, Çakır İ, Ayaz D, Budak A, Sanci M. Clinicopathologic evaluation of uterine smooth muscle tumors of uncertain malignant potential (STUMP): a single center experience. *J Gynecol Obstet Hum Reprod.* 2019;48(8):637–42. https://doi.org/10.1016/j.jogoh.2019.03.003.

26. Lim D, Alvarez T, Nucci MR, et al. Interobserver variability in the interpretation of tumor cell necrosis in uterine leiomyosarcoma. *Am J Surg Pathol.* 2013;37(5):650–8. https://doi.org/10.1097/PAS.0b013e318251162.

27. Oliva E. Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasms. *Mod Pathol.* 2016;29(Suppl 1):S104-120. https://doi.org/10.1038/modpathol.2015.139.

28. Atkins K, Bell S, Kempson R, et al. Epithelioid smooth muscle of the uterus. *Mod Pathol.* 2001;14:132A.

29. Devereaux KA, Kunder CA, Longacre TA. ALK-rearranged tumors are highly enriched in the STUMP subcategory of uterine tumors. *Am J Surg Pathol.* 2019;43(1):64–74. https://doi.org/10.1097/PAS.0000000000001083.

30. Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. *J Clin Oncol.* 1997;15(1):350–62. https://doi.org/10.1200/JCO.1997.15.1.350.

31. Dowsett M, Nielsen TO, A’Hern R, et al. Ki-67 expression in uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS). *Acta Obstet Gynecol Scand.* 2004;83(11):1085–8. https://doi.org/10.1111/j.0001-6349.2004.00502.x.

32. Vissio E, Metovic J, Osella-Abate S, et al. Integration of Ki-67 index into AJCC 2018 staging provides additional prognostic information in breast tumours candidate for genomic profiling. *Br J Cancer.* 2020;122(3):382–7. https://doi.org/10.1038/s41416-019-0656-6.

33. Mayerhofer K, Lozanov P, Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcoma (LMS). *Breast Cancer Res Treat.* 2019;173(3):1097/PAS.0000000000004291.

34. Travaglini A, Raffone A, Gencarelli A, et al. p53, p16 and ki67 as immunohistochemical prognostic markers in uterine smooth muscle tumors of uncertain malignant potential (STUMP). *Pathol Res Pract.* 2021;226:153592. https://doi.org/10.1016/j.prp.2021.153592.

35. Mayerhofer K, Lozanov P, Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcoma (LMS). *Breast Cancer Res Treat.* 2019;173(3):1097/PAS.0b013e3182788466.

36. Davidson B, Kjereng ML, Forsund M, Danielsen HE, Kristensen GB, Abeler VM. Progesterone receptor expression is an independent prognosticator in FIGO Stage I uterine leiomyosarcoma. *Am J Clin Pathol.* 2016;145(4):449–58. https://doi.org/10.1093/ajcp/aqw0630.

37. Chen L, Yang B. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. *Int J Gynecol Pathol.* 2008;27(3):326–32. https://doi.org/10.1097/IGC.0b013e31815ea715.

38. Croce S, Ribeiro A, Brulard C, et al. Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions. *Mod Pathol.* 2015;28(7):1001–10. https://doi.org/10.1038/modpathol.2015.3.

39. Croce S, Ducoulombier A, Ribeiro A, et al. Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors. *Mod Pathol.* 2018;31(5):816–28. https://doi.org/10.1038/modpathol.2017.185.

40. Conconi D, Redaelli S, Lissoni AA, et al. Genomic and epigenomic profile of uterine smooth muscle tumors of uncertain malignant potential (STUMPs) revealed similarities and differences with leiomyomas and leiomyosarcomas. *Int J Mol Sci.* 2021;22(4):1580. https://doi.org/10.3390/ijms22041580.

41. Rizzo A, Ricci AD, Saponara M, et al. Recurrent uterine smooth-muscle tumors of uncertain malignant potential (STUMP): state of the art. *Anticancer Res.* 2020;40(3):1229–38. https://doi.org/10.21873/anticancer.

42. Roberts ME, Aynardi JT, Chu CS. Uterine leiomyosarcoma: a review of the literature and update on management options. *Gynecol Oncol.* 2018;151(3):562–72. https://doi.org/10.1016/j.ygyno.2018.09.010.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.